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Abstract
The human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces apoptosis after
cell cycle arrest at the G2 phase in primate cells. We have reported previously that C81, a carboxy-
terminally truncated form of Vpr, interferes with cell proliferation and results in apoptosis without
G2 arrest. Here, we investigated whether this property of Vpr and C81 could be exploited for use
as a potential anticancer agent. First, we demonstrated that C81 induced G1 arrest and apoptosis
in all tumor cells tested. In contrast, Vpr resulted in G2 arrest and apoptosis in HeLa and 293 T
cells. Vpr also suppressed the damaged-DNA-specific binding protein 1 (DDB1) in HepG2 cells,
thereby inducing apoptosis without G2  arrest. G2  arrest was restored when DDB1 was
overexpressed in cells that also expressed Vpr. Surprisingly, C81 induced G2 arrest when DDB1
was overexpressed in HepG2 cells, but not in HeLa or 293 T cells. Thus, the induction of Vpr- and
C81-mediated cell cycle arrest appears to depend on the cell type, whereas apoptosis was
observed in all tumor cells tested. Overall, Vpr and C81 have potential as novel therapeutic agents
for treatment of cancer.
Background
The human immunodeficiency virus type 1 (HIV-1) acces-
sory gene vpr encodes a 15-kDa protein of 96 amino acids.
Vpr has multiple biological functions, including nuclear
import of the preintegration complex [1-4], transactiva-
tion of the viral promoter [5], regulation of splicing [6-8],
induction of apoptosis, and cell cycle arrest at the G2
phase [9,10]. The induction of cell cycle arrest at G2 is par-
ticularly important because the transcriptional activity of
the HIV-1 long terminal repeat is most active in G2
[11,12], which leads to efficient virus production. Moreo-
ver, the cytostatic activity of Vpr is well conserved among
the primate lentiviruses [13,14]. Thus, Vpr-mediated cell
cycle arrest may play an important role in the life cycle of
HIV-1.
Vpr induces G2 arrest by activating the ataxia telangiecta-
sia-mutated and Rad3-related protein (ATR) [15,16]. ATR
is a sensor of replication stress that is activated by the stall-
ing of replication forks after various cellular insults, such
as deoxyribonucleotide depletion, topoisomerase inhibi-
tion, or UV light induced DNA damage [17]. A recent
report suggests that Vpr induces ATR activation, leading to
the induction of G2 arrest [18]. Additionally, the Vpr-
Published: 12 August 2009
Cancer Cell International 2009, 9:20 doi:10.1186/1475-2867-9-20
Received: 5 March 2009
Accepted: 12 August 2009
This article is available from: http://www.cancerci.com/content/9/1/20
© 2009 Nonaka et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
Page 2 of 10
(page number not for citation purposes)
binding protein (VprBP), which was isolated as a Vpr
coprecipitating protein, acts as a substrate specificity
determinant in a Cul4- and damaged-DNA-specific bind-
ing protein 1 (DDB1)-based E3 ubiquitin ligase complex
[19-22]. Thus, VprBP was renamed the DDB1- and Cul4A-
associated factor 1 (DCAF1). Several groups have recently
confirmed that Vpr physically associates with DCAF1 and
that Vpr is capable of binding to a larger complex consist-
ing of Cul4A, DDB1, and DCAF1 [18,23-27]. The interac-
tion between Vpr and DDB1 could cause the
accumulation of damaged DNA by preventing DNA
repair. The failure of DDB1 to bind DNA and mediate the
repair of DNA lesions generated during S phase may be
sensed by the cell as DNA damage, which would activate
ATR, resulting in G2 arrest followed by apoptosis [26].
However, Vpr mutants such as Vpr(178) or Vpr(R80A) are
able to bind to DCAF1, but are unable to induce G2 arrest
[24,28]. The association of Vpr with the E3 ligase complex
is necessary but not sufficient to induce G2 arrest, suggest-
ing that Vpr may induce the ubiquitination and degrada-
tion of an unknown cellular factor.
Several researchers have demonstrated that Vpr is capable
of inducing cell cycle arrest and apoptosis in cancer cell
lines, including those defective for some tumor suppres-
sor genes and DNA repair genes [29,30]. In addition, Sid-
diqui and colleagues [31] have reported that Vpr is
involved in DNA damage that leads to the disruption of
the cell cycle. These results suggest that Vpr mimics the
action of the anticancer agent cisplatin. Furthermore, it
has also been reported that Vpr has anti-melanoma activ-
ity in vivo [32,33]. These studies suggest that Vpr has the
potential for therapeutic application as a tumor suppres-
sor. Interestingly, we have found that a carboxy-terminally
truncated form of the Vpr, C81, induces G1 arrest, but not
G2 arrest or apoptosis, via disruption of mitochondrial
function [34,35]. We have also shown that caspase-3
activity induced by C81 is higher than that induced by Vpr
in human cells [35]. Thus, our results suggest that C81
may be a strong inducer of tumor cell apoptosis and may
have potential as an anti-tumor agent.
In this study, we examined whether C81, as well as Vpr,
induced cell cycle arrest and apoptosis in several tumor
cell lines, and examined the expression patterns of factors
associated with apoptosis and cell cycle arrest.
Results
The expression of Vpr and C81 induces apoptosis in tumor 
cells
Vpr has previously been demonstrated to induce G2 cell
cycle arrest as well as apoptosis in a number of tumor cells
[29,30]. Previously, we found that C81, a carboxy-termi-
nally truncated form of Vpr, is a strong inducer of apopto-
sis with G1 arrest, but not G2 arrest, of the cell cycle, and
that the apoptotic activity of C81 is stronger than that of
Vpr in human cells [35]. Based on the growth arresting
and apoptosis inducing properties in tumor cells, C81 and
Vpr have potential therapeutic applications for treating
cancer. To further investigate this potential, we examined
whether Vpr and C81 can induce apoptosis in tumor cells.
We transiently transfected two human tumor cell lines,
HeLa and HepG2, as well as 293 T cells, with a pME18Neo
expression vector encoding Flag-tagged wild-type Vpr,
C81, or the empty vector pME18Neo-Flag as a control. We
examined the expression of Vpr and C81, 48 h post-trans-
fection by Western blot analysis using the anti-Flag M2
monoclonal antibody. Fig. 1 shows protein bands with
molecular masses that are consistent with the calculated
masses of the sequences of Flag-tagged Vpr and Flag-
tagged C81.
Next, we detected apoptotic cells by monitoring fluores-
cence after staining the cells with Hoechst 33258. HeLa,
HepG2, and 293 T cells were transfected with the
pME18Neo empty vector, or the expression plasmids for
Vpr or C81. At 48 h post-transfection, cells were fixed and
stained with anti-Flag followed by Alexa-488-conjugated
anti-mouse IgG. To monitor nuclear morphology, cells
were stained with Hoechst 33258. The cells that expressed
either Vpr or C81 had condensed chromatin, a hallmark
of cells undergoing apoptosis (Fig. 2A). Furthermore, we
assessed apoptosis in Vpr- and C81-expressing cells by
measuring the activity of caspase-3, which plays an essen-
Construction and expression of Vpr and C81 Figure 1
Construction and expression of Vpr and C81. (A) Plas-
mids containing cDNA for Vpr and C81 were generated 
from HIV-1NL4-3. Schematic presentation of the predicted 
first α-helical domain (αH1), second α-helical domain (αH2), 
third α-helical domain (αH3) and the arginine rich region of 
Vpr are indicated. (B) Western blotting of wild-type Vpr and 
C81. HeLa, HepG2, and 293 T cells were transfected with 
pME18Neo encoding Flag-tagged wild-type Vpr or C81, or 
the empty vector control pME18Neo-Flag, together with 
pSV-β-galactosidase. Transfected cells were collected and 
lysed 48 h after transfection. Lysates with equal β-galactosi-
dase activity were subjected to Western blot analysis using 
anti-Flag.Cancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
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Vpr and C81 induce apoptosis in tumor cells Figure 2
Vpr and C81 induce apoptosis in tumor cells. (A) HeLa, HepG2, and 293 T cells were transfected with pME18Neo 
encoding Flag-tagged wild-type Vpr or C81, or the control pME18Neo-Flag. At 48 h post-transfection, cells were fixed and 
stained with anti-Flag, followed by Alexa-488-conjugated anti-mouse IgG. Finally, cells were stained with Hoechst 33258 to 
monitor the nuclear morphology. Apoptotic bodies (arrowheads) were identified using confocal laser scanning microscopy. (B) 
HeLa, HepG2, and 293 T cells were transfected with the pME18Neo plasmid encoding Flag-tagged wild-type Vpr or C81, or 
the control pME18Neo-Flag, together with pSV-β-galactosidase. Cells were treated with (filled columns) or without (open col-
umns) inhibitors of caspase-3. At 30 h (293 T), 36 h (HeLa), or 48 h (HepG2) post-transfection, caspase-3 activity was meas-
ured and normalized to the β-galactosidase activity. Each column and error bar represents the mean ± SD of measurements 
from three samples. (C) HeLa, HepG2, and 293 T cells were transfected with pME18Neo encoding Flag-tagged wild-type Vpr 
or C81, or the control pME18Neo-Flag with or without the GFP expression vector pEGFP-N1. GFP was used as a reporter to 
discriminate between transfected and untransfected cells. At 47 h (293 T), 38 h (HeLa), or 58 h (HepG2) post-transfection, 
cells were stained with PE-Annexin V and 7-AAD to identify apoptotic cells, or anti-mouse IgG2b-PE (Nippon BD Company 
Ltd) and 7-AAD as a negative control. The percentages of Annexin V-positive and 7-AAD negative cells relative to GFP-posi-
tive cells indicate the level of Vpr or C81 associated apoptosis.Cancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
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tial role in the induction of apoptosis (Fig. 2B). Caspase-
3 activity was significantly higher in the Vpr- and C81-
expressing cells compared to the control vector transfected
cells. Caspase-3 activity was approximately two-five fold
higher than in the cells transfected with the control
pME18Neo empty vector. Interestingly, caspase-3 activity
was significantly higher in cells that had been transfected
with the C81 expression vector, compared to cells trans-
fected with the Vpr expression vector. Conversely, treat-
ment with the caspase-3 specific inhibitor, Z-DEVD-FMK,
suppressed the activity of caspase-3 in all transfected cells,
including cells transfected with the control pME18Neo
empty vector. These results strongly suggested that Vpr
and C81 can induce apoptosis in the HepG2 and HeLa
cell lines.
The apoptotic activity of Vpr and C81 was further quanti-
fied with flow cytometry by combined staining of trans-
fected samples with phycoerythrin-(PE)-Annexin V and 7-
amino-actinomycin D (7-AAD) (Fig. 2C). A prominent
event in early apoptosis is the exposure of phosphatidyl-
serine (PS) on the outer leaflet of the cell membrane. Cell
surface exposed PS can be specifically detected with PE-
Annexin V. At late stages of apoptosis, or in necrosis, cell
membrane integrity is lost, allowing entry of the DNA-
binding dye 7-AAD into cells. The population of Annexin
V positive and 7-AAD negative apoptotic cells among cells
expressing Vpr or C81 reached to approximately 5.52%
and 7.15% in HeLa cells, respectively, and 10.32% and
12.45% in HepG2 cells, respectively. These values were
much higher than in cells that had been transfected with
the control pME18Neo empty vector or mock transfected
(3.71% and 1.35% in HeLa cells, respectively, and 9.55%
and 0% in HepG2 cells, respectively). Interestingly, the
populations of apoptotic cells in both tumor cell lines
were significantly higher in cells transfected with the C81
expression vector, compared to cells transfected with the
Vpr expression vector. Similar results were obtained with
293 T cells. Only a small population of 293 T cells trans-
fected with either Vpr, C81, or the control vector bound
Annexin V (2.02%, 2.28%, and 1.65%, respectively).
Since these results show the same trends as the Hoechst
33258 staining (Fig. 2A) and the caspase-3 activity (Fig.
2B), we conclude that Vpr and C81 induce apoptosis in
the human tumor cell lines HepG2 and HeLa.
Vpr and C81 induce apoptosis and caspase-9 activity
Vpr and C81 are reported to target mitochondria to
induce apoptosis [10,34]. To examine whether Vpr and
C81 target mitochondria in tumor cells, we measured cas-
pase-8 and caspase-9 activity. Caspase-8 is activated by
FasL and tumor necrosis factor-α (TNF-α), whereas cas-
pase-9 is activated by the disruption of mitochondrial
function. In tumor cells, as well as 293 T cells, caspase-9
activity induced by Vpr or C81 was higher than caspase-8
activity (Fig. 3). Caspase-9 activity in Vpr or C81-trans-
fected cells was significantly higher than in the control
vector transfected cells (p < 0.01). In addition, although
apoptosis induced by Vpr or C81 was significantly inhib-
ited when inhibitors of caspase-9 were added to the Vpr-
or C81-transfected cells (p < 0.01), a caspase-8 inhibitor
only slightly inhibited apoptosis in these transfected cells.
These results suggest that both Vpr and C81 induce apop-
tosis via the activation of caspase-9.
Induction of cell cycle arrest by Vpr and C81 depends on 
the cell type
Vpr induces G2 cell cycle arrest in various human cells
[10], whereas C81 induces G1 cell cycle arrest in human
and rodent cells [34,35]. To determine whether Vpr and
C81 induce cell cycle arrest in HeLa, HepG2, or 293 T
cells, we transfected these cells with pME18Neo encoding
Flag-tagged wild-type Vpr or C81, or the control plasmid
pME18Neo-Flag, together with a small amount of a green
fluorescent protein (GFP) expression vector, pEGFP-N1,
to identify transfected cells. Cells were fixed and stained
with propidium iodide (PI) 48 h post-transfection and
analyzed by flow cytometry. We measured the DNA con-
tent of GFP-positive cells to determine the distribution of
cells across the cell cycle (Fig. 4A). C81 failed to arrest the
cell cycle at the G2 phase in HeLa, 293 T, or HepG2 cells.
To confirm this result, we prepared total cell extracts and
examined cyclin B1, which controls the cell cycle in the G2
phase, by Western blot analysis (Fig. 4B). C81 failed to
induce accumulation of cyclin B1 in HeLa, 293 T, or
HepG2 cells, suggesting that C81 failed to arrest the cell
cycle at the G2 phase in these cells. In contrast, transfec-
tion with Vpr led to an increase in the number of HeLa
and 293 T cells in the G2 phase of the cell cycle, compared
with cells that had been transfected with the control
pME18Neo-Flag. Moreover, Vpr induced accumulation of
cyclin B1 in HeLa and 293 T cells. However, Vpr was una-
ble to arrest the cell cycle at the G2 phase, or to induce
accumulation of cyclin B1, in HepG2 cells (Fig. 4).
DDB1 overexpression enables G2 cell cycle arrest by Vpr 
and C81
It has recently been reported that Vpr targets the DCAF1
adaptor of the Cul4A-DDB1 ligase to induce cell cycle
arrest at the G2 phase [28]. Thus, we examined the expres-
sion levels of DDB1 in various cell lines, including HepG2
cells, which do not arrest at G2 when transfected with Vpr
(Fig. 5A). Interestingly, Western blot analysis revealed that
Vpr, but not C81, could inhibit DDB1 expression in
HepG2 cells. In contrast to Vpr, C81 had no effect on the
expression of DDB1 in HepG2 cells.
To determine the effect of DDB1 in HepG2 cells, we con-
structed a DDB1 expression vector, pDDB1-IRES-GFP,
which was co-transfected with either the Vpr or C81Cancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
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Vpr and C81 induce apoptosis increased caspase-9 activity Figure 3
Vpr and C81 induce apoptosis increased caspase-9 
activity. HeLa, HepG2, and 293 T cells were transfected 
with pME18Neo encoding Flag-tagged wild-type Vpr or C81, 
or the control pME18Neo-Flag, together with pSV-β-galac-
tosidase before treatment with (filled columns) or without 
(open columns) a caspase-8 or caspase-9 inhibitor. At 30 h 
(293 T), 36 h (HeLa), or 48 h (HepG2), post-transfection, 
caspase-8 or caspase-9 activity was measured and normalized 
to the β-galactosidase activity. Columns and error bars rep-
resent the mean ± SD of measurements from three samples.
Induction of cell cycle arrest by Vpr or C81 is dependent on  the cell type Figure 4
Induction of cell cycle arrest by Vpr or C81 is 
dependent on the cell type. (A) HeLa, HepG2, and 293 T 
cells were transfected with pME18Neo encoding Flag-tagged 
wild-type Vpr or C81, or the control pME18Neo-Flag, 
together with the GFP expression plasmid pEGFP-N1. At 48 
h post-transfection, cells were fixed and stained with PI. GFP-
positive cells were analyzed by flow cytometry using CELL 
Quest for acquisition and ModFit LT for quantitative analysis 
of DNA content. Arrows indicate the peaks of cells at the G1 
and G2/M phases. The G2/M:G1 ratios are indicated at the 
upper right in each graph. (B) HeLa, HepG2, and 293 T cells 
were transfected with pME18Neo encoding Flag-tagged wild-
type Vpr or C81, or the control plasmid pME18Neo-Flag, 
together with pSV-β-galactosidase. At 48 h post-transfection, 
the cells were collected and lysed. Lysates with equal β-galac-
tosidase activity were subjected to Western blot analysis 
using a cyclin B1 specific antibody.Cancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
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expression vector. As shown in Fig. 5B, overexpression of
DDB1 resulted in cell cycle arrest at G2 in HepG2 cells
transfected with Vpr. Overexpression of DDB1 had no
effect on the induction of G2 arrest by Vpr in HeLa or 293
T cells. This result clearly suggests that DDB1 plays an
essential role in Vpr-induced cell cycle arrest. Strikingly,
C81, which was completely inactive for G2 arrest in all cell
lines tested, was able to induce G2 arrest in HepG2 cells
overexpressing DDB1, but not in HeLa or 293 T cells over-
expressing DDB1. These results suggest that C81 can cause
G2 arrest independent of its ability to induce apoptosis via
G1 arrest of the cell cycle, although the former activity is
cell type dependent.
Discussion
The results of the present study show that C81 and Vpr
induce apoptosis via the activation of caspase-9 in tumor
cells such as HeLa, HepG2, and 293 T cells. A previous
report indicated that Vpr and C81 induced apoptosis in
rodent cell lines [34], suggesting that the induction of
apoptosis by Vpr and C81 may be ubiquitous. Vpr dis-
played cell type specificity in terms of induction of G2
arrest but not apoptosis. Vpr resulted in apoptosis that
was coupled with G2 arrest in HeLa and 293 T cells,
whereas Vpr induced apoptosis without G2  arrest in
HepG2 cells. Similarly, we previously reported that, in
rodent cell lines, Vpr fails to induce cell cycle arrest at G2
[34]. The present study also shows that DDB1 is required
for Vpr-mediated G2 arrest. Notably, the expression of
Vpr, but not C81, suppressed DDB1 expression in HepG2
cells where it induced apoptosis without G2 arrest. In con-
trast, Vpr induced G2 arrest and apoptosis in HeLa and
293 T cells.
Interestingly, G2 arrest was restored when DDB1 was over-
expressed by transfection during Vpr expression. Addi-
tionally, C81, which was unable to induce G2 arrest in all
cells tested, induced G2 arrest when overexpressed with
DDB1 in HepG2 cells, but not in HeLa or 293 T cells.
These results indicate that the induction of cell cycle arrest
at the G2 phase by Vpr or C81 may depend on the level of
DDB1 expression in Vpr- and C81-transfected cells.
Finally, we demonstrated that the apoptotic properties of
C81, as well as those of Vpr, are strong inducers of intra-
tumoral apoptosis. These proteins hold great promise as
the basis for an anti-cancer treatment, particularly since
C81 caused apoptosis in the tumor cell line HepG2, in
which Vpr failed to induce G2 arrest.
Vpr binding to the adenine nucleotide transporter (ANT)
protein of the inner mitochondrial membrane was previ-
ously shown to induce apoptosis through permeabiliza-
tion of the mitochondrial outer membrane [9]. Vpr has
also been reported to activate caspase-9 and apoptosis in
Overexpression of DDB1 induces G2 cell cycle arrest by Vpr  and C81 Figure 5
Overexpression of DDB1 induces G2 cell cycle arrest 
by Vpr and C81. (A) HeLa, HepG2, and 293 T cells were 
transfected with pME18Neo encoding Flag-tagged wild-type 
Vpr or C81, or the control pME18Neo-Flag, together with 
pSV-β-galactosidase. At 48 h post-transfection, the cells were 
collected and lysed. Lysates with equal β-galactosidase activ-
ity were subjected to Western blotting with either a DDB1 
specific antibody or the Flag-specific MAb M2. (B) HeLa, 
HepG2, and 293 T cells were transfected with pME18Neo 
encoding Flag-tagged wild-type Vpr or C81, or the control 
pME18Neo-Flag, together with the pDDB1-IRES-GFP 
expression plasmid and pSV-β-galactosidase. Lower panel: 48 
h post-transfection, cells were fixed and stained with PI. GFP-
positive cells were analyzed by flow cytometry using CELL 
Quest for acquisition and ModFit LT for quantitative analysis 
of DNA content. Arrows indicate the peaks of cells at the G1 
and G2/M phases. The G2/M:G1 ratio is indicated at the upper 
right in each graph.Cancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
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other human tumor cell lines [29]. Moreover, C81
induced cell cycle arrest at the G1 phase and apoptosis
through activation of caspase-3 and caspase-9 in rodent
cells, which was associated with the release of cytochrome
c from mitochondria into the cytosol and disruption of
the mitochondrial transmembrane potential [34]. We
have demonstrated here that caspase-9 is activated during
Vpr and C81 induced apoptosis, confirming that the
induction of apoptosis by Vpr and C81 is caused by mito-
chondrial dysfunction.
Analysis of the three-dimensional structure of Vpr by
nuclear magnetic resonance (NMR) revealed three well-
defined α-helixes, amino acids 1733 (αH3), 3850 (αH2),
and 5677 (αH3), which are surrounded by flexible
amino- and carboxy-terminal domains [36]. Siddiqui and
colleagues have suggested that the αH2 domain in Vpr is
responsible for DNA damage [31]. Interestingly, Vpr Delta
(3750) failed to induce cell cycle arrest or apoptosis, or to
induce Ku70 or Ku80 expression or suppress tumor
growth. However, the peptide activated the HIV-1 LTR,
resulting in its localization to the nucleus where it pro-
moted nonhomologous end-joining [31]. C81 shares the
αH2 domain with Vpr; thus, C81 may have the ability to
induce DNA damage. In this study, both wild-type Vpr
and C81 induced apoptosis that may be triggered by DNA
damage involving DDB1.
Vpr stabilization was recently reported to be dependent
on DDB1, suggesting that the Cul4A-DDB1-DCAF1 ubiq-
uitin ligase is required to protect Vpr from proteasomal
degradation [37]. Here, we demonstrated that, in HepG2
cells, Vpr was expressed stably despite a decrease in DDB1
expression. Therefore, further studies will be required to
clearly define whether DDB1 protects Vpr from proteaso-
mal degradation in HepG2 cells. Whether this downregu-
lation of DDB1 occurs at the transcriptional or protein
level, and whether the interaction of Vpr with the E3 ligase
complex is involved in the biological activity should also
be addressed in future studies.
The activation of G2 arrest by Vpr is induced via binding
and, possibly, activation of the Cul4A-DDB1-DCAF1
ligase [28]. In addition, DCAF1 engages in simultaneous
interactions with DDB1 and Vpr, leading to the formation
of a ternary complex. The domain of Vpr that binds to
DCAF1 was mapped to the leucine-rich 60LIRILQQLL68
motif in the αH3 domain of Vpr [38]. The truncation of
the C-terminal region of Vpr up to residue H78 or the
replacement of arginine at position 80 by alanine did not
affect the Vpr interaction with DCAF1 but affected the
ability of Vpr to induce G2 arrest [18,24]. Similarly, our
previous results [3,35,39,40] showed that C81, a carboxy-
terminal truncated form of Vpr, was completely inactive
for G2 arrest in all cells tested. Together, these experiments
indicate that interactions between Vpr and DCAF1 are
necessary but not sufficient for the induction of G2 arrest
and that the carboxy-terminal domain of Vpr is likely to
be required for the recruitment of a cellular protein whose
ubiquitination and degradation leads to G2 arrest. Inter-
estingly, we found that C81 resulted in G2 arrest when
overexpressed with DDB1 in HepG2 cells, but not in HeLa
or 293 T cells. This finding suggests that C81 may interact
with DCAF1, causing G2  arrest via activation of the
CUl4A-DDB1-DCAF1 ligase, when DDB1 is overex-
pressed in HepG2 cells. Additionally, the ability of C81 to
induce apoptosis with G1 arrest may be a dominant func-
tion compared to induction of G2 arrest in almost all other
cells. Moreover, the expression of Vpr suppressed DDB1
activity in HepG2 cells but not in HeLa cells or 293 T cells,
resulting in the induction of apoptosis without G2 arrest.
The overexpression of DDB1 succeeded in inducing Vpr-
mediated G2 arrest in HepG2 cells, suggesting that DDB1
is a key component of Vpr-mediated G2 arrest. Thus, the
induction of G2 arrest by Vpr and C81 may be dependent
on the expression level of DDB1.
Conclusion
Vpr has been reported to induce apoptosis in transformed
cells and human tumor cell lines [29,30]. Furthermore,
Vpr successfully induces the regression of murine
melanoma tumors in vivo [33]. Because our data indicate
that Vpr and C81 induce apoptosis in tumor cell lines,
these factors could be potentially useful in the develop-
ment of novel therapeutic treatments for cancer.
Materials and methods
Plasmid construction
The expression vector pME18Neo encoding a Flag-tagged
wild-type Vpr or C81, and the control vector pME18Neo
have been described previously [40,41]. A red-shifted var-
iant of wild-type GFP that has been modified for brighter
fluorescence was encoded by pEGFP-N1 and used as a
reporter to identify transfected cells [42]. Bacterial β-galac-
tosidase encoded by pSV-β-galactosidase was included for
normalization of the transfection efficiency [40]. The
mRNA of human DDB1 was amplified by RT-PCR from
RNA derived from Jurkat cells. RT was performed with an
oligo-dT primer and PCR was performed using the follow-
ing primers: 5'-gcggccgcacatgtcgtacaactacg-3' and 5'-gtc-
gacgctaatggatccgagttagc. The resulting amplicon served as
the template for a second PCR reaction using the primers
5'-ataagaatgcggccgcacatgtcgt-3' and 5'-tggccgacgtc-
gacgctaatggatc-3'. The second PCR product was subcloned
between the NotI-SalI sites of pIRES-hrGFP-2a (Strata-
gene, La Jolla, CA), generating pDDB1-IRES-GFP.
Cell lines and transfection
HeLa cells, which are human epithelial cervical carcinoma
cells [43,44], and 293 T cells that stably express the largeCancer Cell International 2009, 9:20 http://www.cancerci.com/content/9/1/20
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T-antigen of simian sarcoma virus 40 [45] were main-
tained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum
(FCS), penicillin (100 U/ml), and streptomycin (100 μg/
ml). HepG2 cells, which were derived from a well differ-
entiated hepatocellular carcinoma [46,47] were obtained
from the RIKEN Bio Resource Center (Ibaraki, Japan) and
maintained in DMEM supplemented with 10% heat-inac-
tivated FCS, penicillin (100 U/ml), streptomycin (100 μg/
ml), and 0.1 mM non-essential amino acids. Transfection
of cells was performed using FuGENE HD (Roche Diag-
nostics, Basel, Switzerland) according to the manufac-
turer's instructions.
Western blotting
At 24 or 48 h post-transfection with the indicated plas-
mids and pSV-β-galactosidase, cells were washed with
phosphate-buffered saline (PBS) and divided into two
aliquots. One aliquot was subjected to an assay for β-
galactosidase activity with the FluoReporter LacZ/Galac-
tosidase Quantitation kit (Molecular Probes, Eugene,
OR), to monitor the transfection efficiency. The other
aliquot of cells was lysed for 10 min on ice in 10 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 0.1% SDS, 0.1% desoxycholate supplemented with a
protease inhibitor cocktail (Roche Diagnostics, Basel,
Switzerland) and phosphatase inhibitor cocktail1 (Sigma,
St. Louis, Mo). Lysates were centrifuged for 10 min at
20,000 g, mixed with sample buffer for SDS-PAGE and
then boiled for 5 min. Protein concentrations were deter-
mined with a BCA protein assay kit (Pierce, Rockford, IL),
with bovine serum albumin (BSA) as the standard. Aliq-
uots with equal β-galactosidase activity were examined by
Western blotting as described previously [35,39]. An anti-
Flag MAb (M2) (Sigma, St. Louis, MO), anti-Cyclin-B1
(H-20) antibody (Santa Cruz biotechnology, Santa Cruz,
CA), anti-DDB1 MAb (ZYMED Laboratories Invitrogen,
Carlsbad, CA), horseradish-peroxidase (HRP)-conjugated
sheep anti-mouse IgG (Amersham Bioscience, Uppsala,
Sweden) and HRP-conjugated goat anti-rabbit IgGs (Cell
Signaling Technology, Danvers, MA) were used for West-
ern blotting. Signals were visualized after treatment of the
membrane with SuperSignal West Pico chemiluminescent
substrate (Pierce, Rockford, IL).
Analysis of apoptosis
The activities of caspase-3, 8, and 9 were determined using
caspase-3/CPP32, caspase-8/Flice or caspase-9/Mch6
fluorometric assay kits (Bio Vision, Mountain View, CA)
according to the manufacturer's protocols. Briefly, 30 h or
40 h post-transfection, in the presence or absence of 2 μM
caspase-3, 8, or 9 specific inhibitors (Bio Vision, Moun-
tain View, CA), cells were harvested and lysed with cell
lysis buffer. Each cell lysate was incubated with the sub-
strate for 2 h at 37°C. Measurements were made using a
multilabel cell counter (Model1420; Wallac Arvo; Parkin
Elmer, Wellesley, MA).
Hoechst 33258 was used to visualize the condensation
and clumping of chromatin. At 48 h post-transfection
with pME18Neo encoding Flag-tagged wild-type Vpr,
C81, or the control pME18Neo-Flag, HeLa cells that were
grown on coverslips were fixed with 4% formaldehyde
followed by 70% ethanol. Flag-tagged-Vpr or C81 was
detected by indirect immunofluorescent staining with the
Flag-specific MAb M2 (Sigma, St. Louis, MO), followed by
Alexa-488-conjugated anti-mouse IgG. The cells were then
stained with Hoechst 33258 (Sigma, St. Louis, MO).
Apoptotic bodies were characterized using confocal laser
scanning microscopy (FV 1000; Olympus, Tokyo, Japan).
To detect Annexin V positive apoptotic cells, we used flow
cytometry. At the indicated times post-transfection, cell
monolayers were washed with PBS, detached with trypsin
and EDTA, and 1 × 105 cells were stained with 7-amino-
actinomycin D (7-AAD) and Annexin V-PE (Nippon BD
company Ltd, Japan) according to the manufacturer's
instructions. Incubation of cell monolayers for 8 to 13
hours with actinomycin D (2 μg/ml) provided positive
controls for apoptosis. For each sample, 10,000 GFP pos-
itive cells were analyzed using a FACS Calibur instrument
(BD Biosciences, Japan) and the FCS Express version 3
software (De Novo software, CA).
Analysis of the cell cycle
At 48 h post-transfection, cells were harvested and fixed
with 1% formaldehyde and then 70% ethanol. Fixed cells
were incubated in PBS that contained RNase A (50 μg/ml)
at 37°C for 30 min and then stained with PI (50 μg/ml).
The fluorescence of 20,000 cells was analyzed using a
FACS Calibur instrument (Becton-Dickinson, Mountain
View, CA) with the CELL Quest software (Becton-Dickin-
son, Mountain View, CA). Data were extracted after gating
to eliminate cells in which GFP emitted strong fluores-
cence. Ratios of the numbers of cells in the G1 and G2/M
phase (G2/M:G1 ratios) were calculated using the ModFit
LT Software (Verity Software House, Topsham, ME).
Statistical methodology
Statistical analyses were conducted using R version 2.8(1)
[48].
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